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As a result of intensive research during the past 
20 years, there is now a more optimistic attitude 
toward the treatment of children with cancer. Suc-
cess with new therapies of Wilms' tumor and acute 
lymphoblastic leukemia have been important factors 
in generating this new optimism. Despite these and 
other advances, little success has been achieved in 
the treatment of children with neuroblastoma. The 
poor prognosis of these patients is due to the high 
percentage of widespread disease at the time of 
diagnosis and lack of effective treatment for ad-
vanced disease. 
Wilms' tumor and neuroblastoma are numeri-
cally among the most common noncerebral malig-
nant solid tumors in children. The purpose of this 
report is to describe the recent results of therapy. 
Incidence of Wilms' Tumor and Neuroblas-
toma. To provide a perspective of these two diseases, 
a list of malignant diseases in children under 16 
years of age reported to the Medical College of Vir-
ginia Tumor Registry between 1964 and 1970 is 
shown in Table 1. Acute leukemia was the most 
common malignancy, followed by central nervous 
system tumors. Wilms' Tumor accounted for 9.7% 
and neuroblastoma, 6.4 % of all the malignancies 
reported. The importance of these two tumors is 
considerably increased, however, when we consider 
only noncerebral solid tumors of childhood; Wilms' 
tumor accounted for 16 % and neuroblastoma, 11 % 
of these tumors . 
Wilms' Tumor. Advances in chemotherapy of 
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Wilms' tumor, along with improved treatment mo-
dalities in radiotherapy and surgery have increased 
the survival rate from a 20% two-year survival rate 
three decades ago to an 80 % plus rate within the 
last 10-year period. 
The use of dactinomycin and vincristine ac-
counts for the improvement in chemotherapy. In 
the early 1950's, nitrogen mustard was tried in the 
treatment of metastatic Wilms' tumor with little ap-
parent benefit. In 1955, Farber pioneered in the use 
of dactinomycin in children with or without metas-
tases. This drug has been shown, after extensive 
trial, to be of considerable benefit in preventing 
recurrences and in eradicating recurrent and meta-
static disease. 
Improved radiation treatment has resulted from 
the development of more sophisticated equipment 
and from an improved understanding of the natural 
history of Wilms' tumor. Supervoltage equipment 
with increased definition has allowed delivery of 
lower dosages to the tumor, with less radiation scat-
tered into surrounding normal tissue. Additionally, 
less of the dose is directed to growing bone than with 
previous orthovoltage equipment when normal bone 
might absorb as high as 15-20% over that deliv-
ered to the tumor. 
Improved understanding of the disease includes 
the observation that the tumor remains localized in 
its pseudocapsule until the very late stages, allowing 
the use of localized irradiation of the renal fossa 
after surgery rather than more widespread treat-
ment. Another observation that lymph node involve-
ment is rare, saves the need for routine irradiation 
for possible para-aortic node involvement. At the 
same time, greater understanding of the tumor has 
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TABLE 1. 
Pediatric Cases of Malignant Diseases Reported to the 
Medical College of Virginia Tumor Registry, 1964-1970 
NUMBER OF 
DISEASES CASES PERCENT 
Central Nervous System Tumors 
Optic Glioma 5 2.3% 
Astrocytoma 15 6 .9 
Medulloblastoma 9 4.1 
Ependymoma 5 2.3 
Craniopharyngioma 3 1.4 
Meningioma 0 .4 
Acute Leukemia 48 22.2 
Lymphosarcoma 25 11. 5 
Hodgkin's Disease 9 4 . 1 
Wilms' Tumor 21 9.7 
Lymphoepithelioma 7 3.2 
Rhabdomyosarcoma 12 5.5 
Neuroblastoma 14 6.4 
Malignant Schwannoma 3 1.4 
Osteogenic Sarcoma 7 3.2 
Mixed Mesodermal Tumor 2 0.9 
Dysgerminoma 3 1.4 
Carcinoma of the Pancreas 0 .4 
Carcinoma of the Maxillary 
Sinus 4 1.8 
Composite Parotid Tumor 1 0.4 
Retinoblastoma 4 1.8 
Ameloblastoma 3 1. 3 
Arrhenoblastoma 2 0.9 
Ewing's Tumor 2 0.9 
Fibrosarcoma 2 0.9 
Hemangioendothelioma 2 0.9 
Hepatoma and Hepatoblastoma 2 0 .9 
Osteochondroma 2 0.9 
Teratoma 2 0.9 
Total 216 100% 
been developed through the efforts of pathologists, 
with the recognition of a subgroup-the meso-
blastic nephroma. This lesion would seem to be of 
low grade malignancy and may contribute to the well-
known better survival in infants. 
In the presence of lung metastases, which ac-
count for approximately 90% of the cases in which 
Wilms' tumor metastasizes, it has been observed that 
low-dose radiation plus chemotherapy can preserve 
pulmonary function as it cancels disease in at least 
60% of such patients. It has also become evident 
that since two of three patients will have generalized 
pulmonary involvement, bilateral total pulmonary 
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irradiation is necessary even in the patient with 
evidence of only one lesion. 
According to Tefft, experience has shown that 
irradiation cannot be relied upon to control liver 
metastases. Surgical excision is the only sure control 
of a lesion in the liver if it is solitary or localized to 
one lobe. When liver irradiation is indicated, a total 
dose of 3000 rads to the total liver in three weeks 
time should not be exceeded. 
National Wilms' Tumor Study (NWTS). Since 
the national yearly incidence of Wilms' tumor, esti-
mated to be 500, is too small to permit single institu-
tions and investigators to gain significant information 
about the treatment of this disease without the in-
vestigation being unduly protracted, groups of in-
vestigators and institutions combined their efforts 
in a single investigation so that early answers can 
be obtained to longstanding questions regarding 
therapy. 
The primary objective of the NWTS, activated 
in 1969, was to refine methods of treatment. Thus, 
two specific questions were asked: 1) Is post-
operative radiotherapy necessary for treatment of pa-
tients with well-encapsulated, localized lesions after 
what appears to be their total removal? 2) Which 
of the two chemotherapeutic agents ( dactinomycin, 
vincristine) known to be effective against Wilms' 
tumor gives the better result and can this result be 
improved by their combined use? 
The secondary objective was to obtain a better 
understanding of the neoplasm by defining the ex-
tent of the lesion at diagnosis ( clinical grouping or 
staging) and relating it to the response to treatment. 
Five clinical groups (stages) of disease were de-
fined: 
Group I- Tumor limited to the kidney and 
completely resected 
Group II-Tumor extends beyond the kidney 
but is completely resected 
Group III- Residual nonhematogenous tumor 
confined to the abdomen 
Group IV-Hematogenous metastases 
Group V- Bilateral renal involvement either 
initially or subsequently 
Children were randomized at diagnosis accord-
ing to their clinical group determined by the surgeon 
and pathologist. Those in group I were randomized 
following surgery to receive either dactinomycin 
alone or dactinomycin plus postoperative irradiation 
to the tumor bed. Dactinomycin was started and 
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given in five-day courses (15 µg / kg/ d, i.v.) within 
48 hours of diagnosis and repeated at 6 weeks, 3, 6, 
9, 12 and 15 months, thereafter. 
Children in groups II and III, following resec-
tion, all received irradiation to the tumor bed. At the 
same time they were randomized to receive either 
dactinomycin alone, vincristine alone or the combi-
nation. Dactinomycin was administered as outlined 
for group I patients. Vincristine was given weekly 
for 7 weeks ( 1.5 mg/ m2 i.v.) starting at the time of 
diagnosis, then at 3, 6, 9, 12 and 15 months there-
after, giving two doses four days apart. 
Children in group IV received either a pre-
operative course of vincristine ( day O and 7) and 
then had surgery on day 14 or surgery was carried 
out immediately. Treatment then was identical to 
that for groups II and III. 
Results. It is still too early to draw any definite 
conclusions from any of the preliminary data. Certain 
patterns seem to be emerging, however, and are 
worthy of mention. 
Of 208 patients registered, 21 were incorrectly 
diagnosed. More than half of these cases turned out 
to be either neuroblastoma or polycystic kidney. 
Other diagnoses included renal carbuncle, benign 
teratoma, congenital renal vein thrombosis, hemor-
rhage into the subrenal gland, hypernephroma and 
rhabdomyosarcoma. Two cases of mesoblastic ne-
phroma were also registered. 
One hundred eighty-seven patients were ran-
domized according to protocol. Patients with clinical 
group I disease (the lesion limited to the kidney 
and completely resected) formed the most frequent 
group and accounted for 83 of these patients. Dis-
ease groups II, III and IV were less frequent and 
contained 47, 39 and 18 patients respectively. The 
accrual rate by month has shown no seasonal varia-
tion in the incidence of the disease. 
The mean age at diagnosis for the entire series 
of 187 patients was 41 months. Group I patients 
were the youngest (approximately 30 months) and 
group IV, the oldest ( approximately 60 months). 
The mean ages of groups II and III were approxi-
mately equal at 39 months. From the data, it seems 
clear that with increasing age at diagnosis, the dis-
ease is likely to be more advanced. 
Approximately 16% of all the patients were 
black and 48 % were females. The right kidney was 
involved in 46% of the cases. No differences were 
apparent among the four groups in these parameters. 
With regard to the results of therapy, approxi-
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mately 90% of the patients in clinical group I were 
free of disease from one to more than 21 months 
after treatment was instituted. There is no difference 
in recurrence rate thus far between those who received 
dactinomycin alone and those who received it in 
combination with postoperative radiotherapy. If fur-
ther follow-up substantiates that radiotherapy pro-
duces no added benefit in this clinical group, the 
study will have borne important fruits . The possible 
untoward late effects of radiation are well known. 
Disturbances of normal bone growth, radiation ne-
phritis, radiation hepatitis and pulmonary fibrosis 
are some. Induction of primary tumor by the irra-
diation of normal structures, while not frequent, is 
nonetheless a matter of real concern. 
Of those with clinical groups II and III involve-
ment, approximately 75% continued in complete 
remission from one to 21 months after the start of 
treatment and approximately 60% of these in clini-
cal group IV were similarly free of disease for the 
same period of time. No differences are apparent 
thus far between the various treatment regimens in 
these three groups. 
All but one of the metastases or recurrences in 
relapsed patients developed during the first year of 
treatment. By far, the most common site of metas-
tases was the lung. Other sites were liver, nodes, 
bone, spleen and brain. Abdominal recurrences were 
infrequent. In most instances death was attributed to 
tumor, but in a few cases no tumor was found and 
infection was thought to be the cause. 
Toxicities to therapy included leukopenia and 
thrombocytopenia with occasional anemia, nausea 
and vomiting, radiation dermatitis and hepatitis and 
alopecia. These were usually reversible. 
At the Medical College of Virginia, 11 patients, 
ranging in age from five months to eight years, have 
been entered on study (Table 2). Three had clinical 
group I disease, seven, clinical group II disease, and 
one, clinical group IV disease. All but one attained 
complete remission with therapy. Two of the 11 de-
veloped metastases at 13 and 16 months following 
diagnosis and one of them has expired. Eight of the 
11 are free of disease from five months to nearly 
three years after treatment was started. The three 
oldest patients ( 31 2 , 5 and 8 years) in this small 
series developed recurrences or metastases. 
Neuroblastoma. Although there has been 
marked improvement in survival of children with 
Wilms' tumor during the last decade, this has not 
been the case for metastatic and nonmetastatic 
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TABLE 2. 
National Wilms' Tumor Study Medical College of Virginia Patients 
CASE AGE AT DIAGNOSIS DATE ON STUDY CLINICAL GROUP TREATMENT STATUS 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
19 mos. 
10 mos. 
23 mos. 
5 yrs. 
2 yrs. 
2 yrs. 
8! mos. 
l yr. 
3! yrs. 
5 mos. 
8 yrs. 
S- Surgery 
R- Radiotherapy 
Dact- Dactinomycin 
Vcr- Vincristine 
NED- No evidence of disease 
4/ 10/ 70 
6/ 29 / 70 
2/ 28 / 72 
10 / 29 / 69 
5/ 14/ 70 
8/26/ 70 
3 / 19 / 71 
7 / 1 /71 
10/ 11 / 71 
9 / 16/ 72 
4/ 6/71 
neuroblastoma for the same time period, primarily 
due to the diffculty in early diagnosis and lack of 
effective treatment for advanced disease. Chemo-
therapy, in contrast to Wilms' tumor, has not been 
very successful. An overaH cure rate of 35-40% 
has been reported. In patients under one year of age 
who have localized disease, survival rates as high as 
68-70% have been achieved; however, in general-
ized- disease the survival rate has been estimated 
at about 12%. 
Between 1957 and 1968, 21 children with 
neuroblastoma and two children with ganglioneuro-
blastoma were treated at the Medical College of 
Virginia. Of the entire group, only two patients are 
alive; one child with intratboracic neuroblastoma, 
age five months at diagnosis, has no evidence of 
disease after resection and postoperative radio-
therapy. Another, age 6 months at diagnosis with 
widespread disease, has been free of disease for four 
years, after one year of treatment with cyclophospha-
mide and vincristine. Six of the patients were under 
one year of age, and 14 were two years or older at 
diagnosis. 
The commonest site of the primary tumor was 
the adrenal gland ( 52 % ) . Other less common sites 
included the retroperitoneum ( 17 % ) , posterior me-
dias tin um ( 17 % ) and the brain ( 4 % ) . 
In the majority of cases (74% ), the disease 
I 
I 
I 
II 
II 
II 
II 
II 
II 
II 
IV 
S, R, Dact 
S, R, Dact 
S, R, Dact 
S, R, Dact, Ver 
S, R, Dact, Ver 
S, R, Dact, Ver 
S, R , Ver 
S, R, Ver 
S, R, Ver later Dact 
Adriamycin Cytoxan 
S, R, Ver 
S, R , Dact, Ver 
NED 
NED 
NED 
Expired 1 / 4/ 71 
NED 
NED 
NED 
NED 
Expired 2/ 5/ 72 
(no response) 
NED 
Recurrence right lung 
8 / 72, later brain 
was already widespread at the time of initial exami-
nation. Distent metastases occurred most often in 
bones ( 48 % ) , bone marrow ( 48 % ) , and liver 
( 48 % ) , although at autopsy an unusually high per-
centage (35%) had metastases to the lungs and 
pleura. Those with regional disease developed metas-
tases within 12 months of diagnosis. Only three 
children, all with regional disease, had complete re-
section of tumor. All others had either partial resec-
tion or biopsy. 
Four children died before any treatment could 
be instituted. Fifteen of 23 received postoperative 
radiotherapy. A variety of chemotherapeutic agents 
including vincristine and cyclophosphamide were 
included as part of the initial treatment program in 
15 patients with distent metastases and in four with 
regional disease. 
The median survival time for the entire group 
was six months, with the longest survivor still alive 
at seven years . Those with the primary site located 
in the adrenal gland had the shortest median survival 
time ( 4 months). 
Sawitsky and Desposito (3) have reported their 
results using either cyclic or sequential vincristine 
and cyclophosphamide in high or low dosage for 
treatment of generalized neuroblastoma. Their results 
also do not bear out the early enthusiasm shown for 
these agents for treatment of neuroblastoma. Of 4 7 
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STAGE I: 
TABLE 3 
Staging of Neuroblastoma 
Tumor confined to the organ or structure of 
origin. 
STAGE II: Tumors extending in continuity beyond the 
organ or structure of origin but not crossing 
the midline. Regional lymph nodes on the 
homolateral side may be involved. 
STAGE III : Tumors extending in continuity beyond the 
midline. Regional lymph nodes may be involved 
bilaterally. 
STAG E IV : Remote disease involving skeleton, organs, 
soft tissue, distant lymph node groups, etc. 
(See IV-S.) 
STAGE IV-S: Patients who would otherwise be Stage I or II, 
but who have remote disease confined only 
to one or more of the following sites : liver, 
skin or bone marrow (without radiographic 
evidence of bone metastases on complete 
skeletal survey). 
patients treated, only two are alive for more than 24 
months with no evidence of disease. The median sur-
vival in the whole group was 37 weeks. If a response 
occurred, median survival was prolonged to 65 weeks. 
Other drugs used have also produced disap-
pointing results and include 6-mercaptopurine, pred-
nisone, methotrexate, dactinomycin, daunorubicin, 
and nitrogen mustard. Newer agents such as adria-
mycin and ifosphamide are currently under investi-
gation. 
Although results of treatment continue to be 
poor, advances have been made in the understanding 
of the disease process. A new staging system has 
been developed based on certain patterns of origin 
and clinical behavior found to affect prognosis, 
which takes into account the peculiarities unique for 
neuroblastoma (Table 3) ( 1). Data based on this 
system indicates that: 1) Patients with stage IV-S 
have a better prognosis than those with stage IV 
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disease; 2) The proportion of patients in stages III 
and IV increases with age; 3) The presence of bone 
metastases, to be distinguished from bone marrow 
involvement with positive x-ray findings, almost al-
ways heralds a fatal outcome; and 4) Data confirm 
the well-known better survival of patients under one 
year of age. 
A second potential contribution has been the 
development of a simple, reliable "dip-stick" test 
for detecting the early presence of neuroblastoma 
( 2). The test is based on the fact that up to 80 % 
of the children with this disease excrete excess 
catecholamine or one of its metabolites, 3-methoxy-
4-hydroxy-mandelic acid (VMA) in the urine. 
Strips of chromatography paper impregnated with 
paranitroaniline, sodium nitrate, and anhydrous 
potassium carbonate are dipped into a urine sample 
or just pressed against a wet diaper. Within ten 
minutes, the color of the paper changes to orange 
or purple if either VMA or normetanephrine is pres-
ent in urine. The test may be used by private prac-
ticing physicians for routine screening on all chil-
dren under five years of age. If used at regular 
yearly intervals, it is conceivable that a significant 
impact upon survival of neuroblastoma may be 
achieved by early diagnosis before metastasis has 
occurred. 
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